Literature DB >> 17283139

Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors.

Yakov Krelin1, Elena Voronov, Shahar Dotan, Moshe Elkabets, Eli Reich, Mina Fogel, Monika Huszar, Yoichiro Iwakura, Shraga Segal, Charles A Dinarello, Ron N Apte.   

Abstract

The role of microenvironment interleukin 1 (IL-1) on 3-methylcholanthrene (3-MCA)-induced carcinogenesis was assessed in IL-1-deficient mice, i.e., IL-1beta(-/-), IL-1alpha(-/-), IL-1alpha/beta(-/-) (double knockout), and mice deficient in the naturally occurring inhibitor of IL-1, the IL-1 receptor antagonist (IL-1Ra). Tumors developed in all wild-type (WT) mice, whereas in IL-1beta-deficient mice, tumors developed slower and only in some of the mice. In IL-1Ra-deficient mice, tumor development was the most rapid. Tumor incidence was similar in WT and IL-1alpha-deficient mice. Histologic analyses revealed fibrotic structures forming a capsule surrounding droplets of the carcinogen in olive oil, resembling foreign body-like granulomas, which appeared 10 days after injection of 3-MCA and persisted until the development of local tumors. A sparse leukocyte infiltrate was found at the site of carcinogen injection in IL-1beta-deficient mice, whereas in IL-1Ra-deficient mice, a dense neutrophilic infiltrate was observed. Treatment of IL-1Ra-deficient mice with recombinant IL-1Ra but not with an inhibitor of tumor necrosis factor abrogated the early leukocytic infiltrate. The late leukocyte infiltrate (day 70), which was dominated by macrophages, was also apparent in WT and IL-1alpha-deficient mice, but was nearly absent in IL-1beta-deficient mice. Fibrosarcoma cell lines, established from 3-MCA-induced tumors from IL-1Ra-deficient mice, were more aggressive and metastatic than lines from WT mice; cell lines from IL-1-deficient mice were the least invasive. These observations show the crucial role of microenvironment-derived IL-1beta, rather than IL-1alpha, in chemical carcinogenesis and in determining the invasive potential of malignant cells.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17283139     DOI: 10.1158/0008-5472.CAN-06-2956

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  113 in total

1.  Interleukin-10 ablation promotes tumor development, growth, and metastasis.

Authors:  Takashi Tanikawa; Cailin Moira Wilke; Ilona Kryczek; Grace Y Chen; John Kao; Gabriel Núñez; Weiping Zou
Journal:  Cancer Res       Date:  2011-11-28       Impact factor: 12.701

2.  STAT2 contributes to promotion of colorectal and skin carcinogenesis.

Authors:  Ana M Gamero; Matthew R Young; Roycelynn Mentor-Marcel; Gerd Bobe; Anthony J Scarzello; Jennifer Wise; Nancy H Colburn
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-16

3.  IL-1β regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function.

Authors:  Moshe Elkabets; Vera S G Ribeiro; Charles A Dinarello; Suzanne Ostrand-Rosenberg; James P Di Santo; Ron N Apte; Christian A J Vosshenrich
Journal:  Eur J Immunol       Date:  2010-12       Impact factor: 5.532

4.  Human herpesvirus-encoded kinase induces B cell lymphomas in vivo.

Authors:  Penny M Anders; Nathan D Montgomery; Stephanie A Montgomery; Aadra P Bhatt; Dirk P Dittmer; Blossom Damania
Journal:  J Clin Invest       Date:  2018-05-07       Impact factor: 14.808

5.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

6.  An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.

Authors:  Ivona Aksentijevich; Seth L Masters; Polly J Ferguson; Paul Dancey; Joost Frenkel; Annet van Royen-Kerkhoff; Ron Laxer; Ulf Tedgård; Edward W Cowen; Tuyet-Hang Pham; Matthew Booty; Jacob D Estes; Netanya G Sandler; Nicole Plass; Deborah L Stone; Maria L Turner; Suvimol Hill; John A Butman; Rayfel Schneider; Paul Babyn; Hatem I El-Shanti; Elena Pope; Karyl Barron; Xinyu Bing; Arian Laurence; Chyi-Chia R Lee; Dawn Chapelle; Gillian I Clarke; Kamal Ohson; Marc Nicholson; Massimo Gadina; Barbara Yang; Benjamin D Korman; Peter K Gregersen; P Martin van Hagen; A Elisabeth Hak; Marjan Huizing; Proton Rahman; Daniel C Douek; Elaine F Remmers; Daniel L Kastner; Raphaela Goldbach-Mansky
Journal:  N Engl J Med       Date:  2009-06-04       Impact factor: 91.245

Review 7.  The interleukin-1 family: back to the future.

Authors:  Cecilia Garlanda; Charles A Dinarello; Alberto Mantovani
Journal:  Immunity       Date:  2013-12-12       Impact factor: 31.745

8.  High expression level of interleukin-1β is correlated with poor prognosis and PD-1 expression in patients with lung adenocarcinoma.

Authors:  X Ding; J Zhang; M Shi; D Liu; L Zhang; R Zhang; B Su; K Ai
Journal:  Clin Transl Oncol       Date:  2020-05-29       Impact factor: 3.405

9.  Immunomodulatory properties of silver nanoparticles contribute to anticancer strategy for murine fibrosarcoma.

Authors:  Biswajit Chakraborty; Ramkrishna Pal; Mohammed Ali; Leichombam Mohindro Singh; Dewan Shahidur Rahman; Sujit Kumar Ghosh; Mahuya Sengupta
Journal:  Cell Mol Immunol       Date:  2015-05-04       Impact factor: 11.530

10.  Critical role for IL-1β in DNA damage-induced mucositis.

Authors:  Naama Kanarek; Sergei I Grivennikov; Michael Leshets; Audrey Lasry; Irit Alkalay; Elad Horwitz; Yoav D Shaul; Matthew Stachler; Elena Voronov; Ron N Apte; Michele Pagano; Eli Pikarsky; Michael Karin; Sankar Ghosh; Yinon Ben-Neriah
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-27       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.